Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$4.94 – $5.09
Volume20,417
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.56M
Price / earnings
—
Price / book
0.59×
Price / sales
—
EV / sales
—
EV / EBITDA
0.37×
Profitability
Earnings per share
-$11.35
Return on assets
-110.05%
Return on equity
-133.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.37×
Quick ratio
5.37×
Cash ratio
5.07×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.27M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AEMD, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.68M
$1.58M
$1.93M
$2.06M
$1.51M
$1.79M
$2M
$1.81M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$2.68M
$1.58M
$1.93M
$2.06M
$1.51M
$1.79M
$2M
$1.81M
Operating income
-$2.68M
-$1.58M
-$1.93M
-$2.06M
-$1.51M
-$1.79M
-$2M
-$1.81M
Interest expense
$0
$0
-$111.5K
$43.87K
$0
$0
-$214.32K
$59.96K
Income before taxes
-$2.62M
-$1.55M
-$1.88M
-$2.02M
-$1.49M
-$1.76M
-$6.25M
-$1.75M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.62M
-$1.55M
-$1.88M
-$2.02M
-$1.49M
-$1.76M
-$6.25M
-$1.75M
Net income attributable to common shareholders
-$2.62M
-$1.55M
-$1.88M
-$2.02M
-$1.49M
-$1.76M
-$6.25M
-$1.75M
EBITDA
-$2.59M
-$1.51M
-$1.85M
-$1.98M
-$1.43M
-$1.71M
-$1.92M
-$1.73M
Basic earnings per share
-$2.60
-$4.02
-$7.43
-$12.25
-$18.70
-$42.42
-$171.49
-$50.25
Diluted earnings per share
-$2.60
-$4.02
-$7.43
-$12.25
-$18.70
-$42.42
-$171.49
-$50.25
Recent news
Company coverage with links to the original publishers.
Aethlon Medical announced that its independent Data Safety Monitoring Board (DSMB) has recommended advancing to the third and final cohort of its clinical trial for the Hemopurifier device. The DSMB found no safety concerns in the second cohort data, with no serious adverse events or dose-limiting toxicities reported. The final cohort will enroll 9-18 patients receiving three treatments over one week at three Australian clinical sites.
Totaligent Inc. (OTC: TGNT) announced the execution of a binding Letter of Intent with GloMed Solutions, a Japanese medical aesthetics and biologics distributor generating ~$10M in annual revenue. The agreement establishes a joint venture integrating Totaligent's Aetherium Medical platform with GloMed's operations, while granting Totaligent a binding call option to fully acquire GloMed within one year. The JV is targeted to close around March 22, 2026, positioning the company in the rapidly growing biologics and medical tourism sectors.
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing the Hemopurifier device for cancer and infectious disease treatment, announced it will release fiscal Q3 2025 financial results on February 12, 2026, at 4:15 p.m. ET, followed by a management conference call at 4:30 p.m. ET. The Hemopurifier has received FDA Breakthrough Device designations for advanced/metastatic cancer and life-threatening viral infections.
Aethlon Medical published preclinical study showing their Hemopurifier device can bind and remove extracellular vesicles from Long COVID patient samples, potentially decreasing inflammatory microRNAs and offering a novel therapeutic approach.
Aethlon Medical reported Q2 2025 financial results, highlighting clinical progress in oncology trials, ongoing Long COVID research, and significant cost reductions of 48% in operating expenses.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.